Publicaciones científicas

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

30-sep-2022 | Revista: Science Advances

Paula Rodriguez-Marquez  1 , Maria E Calleja-Cervantes  1   2 , Guillermo Serrano  2 , Aina Oliver-Caldes  3 , Maria L Palacios-Berraquero  4 , Angel Martin-Mallo  1 , Cristina Calviño  4 , Marta Español-Rego  5 , Candela Ceballos  6 , Teresa Lozano  7 , Patxi San Martin-Uriz  1 , Amaia Vilas-Zornoza  1   8 , Saray Rodriguez-Diaz  1 , Rebeca Martinez-Turrillas  1   8 , Patricia Jauregui  4 , Diego Alignani  9 , Maria C Viguria  6 , Margarita Redondo  6 , Mariona Pascal  5 , Beatriz Martin-Antonio  3 , Manel Juan  5   10 , Alvaro Urbano-Ispizua  3 , Paula Rodriguez-Otero  4 , Ana Alfonso-Pierola  4   8 , Bruno Paiva  1   8   9 , Juan J Lasarte  7 , Susana Inoges  4   8   11 , Ascension Lopez-Diaz de Cerio  4   8   11 , Jesus San-Miguel  1   4   8   12 , Carlos Fernandez de Larrea  3 , Mikel Hernaez  2   8   13 , Juan R Rodriguez-Madoz  1   8 , Felipe Prosper  1   4   8   12


Abstract

Identification of new markers associated with long-term efficacy in patients treated with CAR T cells is a current medical need, particularly in diseases such as multiple myeloma. In this study, we address the impact of CAR density on the functionality of BCMA CAR T cells.

Functional and transcriptional studies demonstrate that CAR T cells with high expression of the CAR construct show an increased tonic signaling with up-regulation of exhaustion markers and increased in vitro cytotoxicity but a decrease in in vivo BM infiltration.

Characterization of gene regulatory networks using scRNA-seq identified regulons associated to activation and exhaustion up-regulated in CARHigh T cells, providing mechanistic insights behind differential functionality of these cells. Last, we demonstrate that patients treated with CAR T cell products enriched in CARHigh T cells show a significantly worse clinical response in several hematological malignancies.

In summary, our work demonstrates that CAR density plays an important role in CAR T activity with notable impact on clinical response.

CITA DEL ARTÍCULO  Sci Adv. 2022 Sep 30;8(39):eabo0514.  doi: 10.1126/sciadv.abo0514

Nuestros autores

Dra. Paula Rodríguez Márquez
Dr. Juan Roberto Rodríguez Madoz
Dr. Mikel Hernáez Arrazola
Investigador | Investigador principal Programa de Biología Computacional
Mª Erendira Calleja Cervantes
Técnico de Investigación Bioinformático Grupo de Investigación en Terapia Celular Adoptiva
Guillermo Serrano Sanz
Técnico de Investigación Bioinformático Plataforma Bioinformática
Ángel Martín Mallo
Dr. Patxi San Martín Uriz
Investigador Adscrito a Proyecto Programa de Investigación de Hemato-Oncología
Saray Rodríguez Díaz
Rebeca Martínez Turrillas
Diego Alignani
Técnico de laboratorio Plataforma de Citometría
Dra. Teresa Lozano Moreda
Investigadora | Investigadora principal Programa de Investigación de Inmunología e Inmunoterapia